AtriCure Q3 2024 Adj. EPS $(0.17) Beats $(0.19) Estimate, Sales $115.910M Beat $112.254M Estimate
Portfolio Pulse from Benzinga Newsdesk
AtriCure reported better-than-expected Q3 2024 results with an adjusted EPS of $(0.17), beating the estimate of $(0.19), and sales of $115.910 million, surpassing the $112.254 million estimate. Sales increased by 17.93% compared to the same period last year.
October 29, 2024 | 8:03 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
AtriCure's Q3 2024 earnings report shows a smaller-than-expected loss and higher-than-expected sales, indicating strong performance and growth compared to last year.
AtriCure's Q3 2024 results exceeded analyst expectations for both EPS and sales, with a significant year-over-year sales increase. This positive performance is likely to boost investor confidence and positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100